EMEA-003418-PIP01-23 - paediatric investigation plan

Tiragolumab

atezolizumab

Key facts

• Active Substance:
  • Tiragolumab
  • atezolizumab
• Therapeutic area:
  Oncology
• Decision number:
  P/0328/2023
• PIP number:
  EMEA-003418-PIP01-23
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of lung carcinoma
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  08/08/2023

Decision

P/0328/2023 : EMA decision of 8 August 2023 on the granting of a product specific waiver for tiragolumab/atezolizumab, (EMEA-003418-PIP01-23)

Reference Number: EMA/344548/2023